Emicizumab prophylaxis and health-related outcomes in persons with hemophilia a (PwHA) with inhibitors: HAVEN 1 study

被引：0

作者：

Oldenburg, J. ^{[1
]}

Mahlangu, J. N. ^{[2
,3
]}

Bujan, W. ^{[4
]}

Trask, P. C. ^{[5
]}

von Mackensen, S. ^{[6
]}

Callaghan, M. U. ^{[7
]}

Young, G. ^{[8
]}

Asikanius, E. ^{[9
]}

Peyvandi, F. ^{[10
]}

Santagostino, E. ^{[10
]}

Kruse-Jarres, R. ^{[11
]}

Negrier, C. ^{[12
]}

Kessler, C. ^{[13
]}

Levy, G. G. ^{[14
]}

Windyga, J. ^{[15
]}

Shima, M. ^{[16
]}

机构：

[1] Univ Klinikum Bonn, Bonn, Germany

[2] Univ Witwatersrand, Fac Hlth Sci, Haemophilia Comprehens Care Ctr, Johannesburg, South Africa

[3] NHLS, Johannesburg, South Africa

[4] Inst Costarricense Invest Cient, San Jose, Costa Rica

[5] Genentech Inc, San Francisco, CA 94080 USA

[6] Univ Med Ctr Hambur Eppendorf, Dept Med Psychol, Hamburg, Germany

[7] Childrens Hosp Michigan, Detroit Med Ctr, Detroit, MI 48201 USA

[8] Univ Southern Calif, Keck Sch Med, Childrens Hosp Los Angeles, Los Angeles, CA USA

[9] F Hoffmann La Roche Ltd, Basel, Switzerland

[10] Osped Maggiore Policlin, IRCCS Ca Granda Fdn, Milan, Italy

[11] Univ Washington, Washington Ctr Bleeding Disorders BloodWorks NW, Seattle, WA 98195 USA

[12] Univ Claude Bernard, Louis Pradel Cardiol Hosp, Lyon, France

[13] Georgetown Univ, Med Ctr, Washington, DC 20007 USA

[14] Genentech Inc, Pharma Dev Oncol, San Francisco, CA 94080 USA

[15] Inst Hematol & Transfus Med, Warsaw, Poland

[16] Nara Med Univ, Dept Pediat, Kashihara, Nara, Japan

来源：

HAEMOPHILIA | 2018年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P120

引用

页码：89 / 90

页数：2

共 50 条

[21] EMICIZUMAB PROPHYLAXIS IMPROVES ACUTE AND CHRONIC PAIN-RELATED OUTCOMES IN PEOPLE WITH HAEMOPHILIA A (PWHA): POST HOC ANALYSIS OF 470 PATIENTS FROM HAVEN 1, 3, 4 AND STASEY
Hermans, C.
Skinner, M. W.
Gentile, B.
Lim, E.
Minhas, M.
Moreno, K.
Tzeng, E.
Buckner, T. W.
HAEMOPHILIA, 2023, 29 : 79 - 80
[22] Inhibitory Body Hemophilia A HAVEN-I Study demonstrates Efficacy of Bleeding Prophylaxis with Emicizumab
不详
TRANSFUSION MEDICINE AND HEMOTHERAPY, 2017, 44 (02) : 118 - 118
[23] Model of Short and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia.
Mahajerin, Arash
Zhou, Zheng-Yi
Raimundo, Karina
Patel, Anisha
Han, Simeng
Ji, Yusi
Zhong, Jia
Betts, Keith
BLOOD, 2018, 132
[24] Model of Short- and Long-Term Outcomes of Emicizumab Prophylaxis Treatment for Persons with Hemophilia A
Zhou, Zheng-Yi
Raimundo, Karina
Patel, Anisha M.
Han, Simeng
Ji, Yusi
Fang, Honghao
Zhong, Jia
Betts, Keith A.
Mahajerin, Arash
JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2020, 26 (09): : 1109 - +
[25] Development and testing of the Satisfaction Questionnaire with Intravenous or Subcutaneous Hemophilia Injection and results from the Phase 3 HAVEN 3 study of emicizumab prophylaxis in persons with haemophilia A without FVIII inhibitors
Kempton, Christine
Trask, Peter
Parnes, Aric
Niggli, Markus
Campinha-Bacote, Avrita
Callaghan, Michael U.
O'Connell, Niamh
Paz-Priel, Ido
Mahlangu, Johnny N.
HAEMOPHILIA, 2021, 27 (02) : 221 - 228
[26] HEALTH-RELATED QUALITY OF LIFE (HRQOL) IMPROVES IN PEOPLE WITH HEMOPHILIA A OR B (PWHA/B) WITH INHIBITORS RECEIVING FITUSIRAN PROPHYLAXIS: RESULTS OF PHASE 3 ATLAS-INH
Negrier, C.
Young, G.
Sun, J.
Wu, R.
Qiu, Z.
Andersson, S.
Mei, B.
Cano, V.
Bartelt-Hofer, J.
Srivastava, A.
HAEMOPHILIA, 2022, 28 : 57 - 58
[27] Emicizumab Prophylaxis for the Treatment of Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Interim Analysis of the HAVEN 7 Study
Pipe, Steven W.
Collins, Peter
Dhalluin, Christophe
Kenet, Gili
Schmitt, Christophe
Buri, Muriel
Jimenez-Yuste, Victor
Peyvandi, Flora
Young, Guy
Oldenburg, Johannes
Mancuso, Maria Elisa
Kiialainen, Anna
Chang, Tiffany
Lehle, Michaela
Fijnvandraat, Karin
BLOOD, 2022, 140
[28] Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies (vol 137, pg 2231, 2021)
不详
BLOOD, 2023, 142 (15) : 1329 - 1329
[29] Factor VIII Use in the Treatment of Breakthrough Bleeds in Hemophilia A Patients without Inhibitors on Emicizumab Prophylaxis: The Phase 3 HAVEN 3 Study Experience
Callaghan, Michael
Trzaskoma, Benjamin
Ko, Richard H.
Lee, Lucy
Patel, Anisha M.
Tzeng, Eunice
Shah, Michelle Lynn
Chang, Tiffany Y.
Niggli, Markus
Dhalluin, Christophe
Mahlangu, Johnny
BLOOD, 2019, 134
[30] The effect of emicizumab prophylaxis on long-term, self-reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
Skinner, Mark W.
Negrier, Claude
Paz-Priel, Ido
Chebon, Sammy
Jimenez-Yuste, Victor
Callaghan, Michael U.
Lehle, Michaela
Niggli, Markus
Mahlangu, Johnny
Shapiro, Amy
Shima, Midori
Campinha-Bacote, Avrita
Levy, Gallia G.
Oldenburg, Johannes
von Mackensen, Sylvia
Pipe, Steven W.
HAEMOPHILIA, 2021, 27 (05) : 854 - 865

← 1 2 3 4 5 →